References for CBER200219 Biological Products; Bacterial Vaccines and Toxoids; Implementation of Efficacy Review; Final Rule and Final Order

1. Brachman, P. S., H. Gold, S. Plotkin, F. R. Fekety, M. Werrin, and N. R. Ingraham, "Field Evaluation of a Human Anthrax Vaccine," *American Journal of Public Health*, 52:632-645, 1962.
2. Lois M. Joellenbeck, Lee L. Zwanziger, Jane S. Durch, and Brian L. Strom, Editors, Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-Up Agency, *The National Academies Press*, Washington, DC, *http://www.nap.edu/catalog/10310.html.*
3. Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. M. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander, "Efficacy of a Human Anthrax Vaccine in Guinea Pigs, Rabbits, and Rhesus Macaques Against Challenge by Bacillus Anthracis Isolates of Diverse Geographical Origin," *Vaccine*, 19(23-24):3241-3247, 2001.
4. Ivins, B. E., P. F. Fellows, M. L. M. Pitt, J. E. Estep, S. L. Welkos, P. L.Worsham and A. M. Friedlander, "Efficacy of a Standard Human Anthrax Vaccine Against Bacillus Anthracis Aerosol Spore Challenge in Rhesus Monkeys," *Salisbury Medical Bulletin* 87(Suppl.):125-126, 1996.
5. Ivins, B. E., M. L. M. Pitt, P. F. Fellows, J. W. Farchaus, B. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, P. H. Gibbs, and A. M. Friedlander, "Comparative Efficacy of Experimental Anthrax Vaccine Candidates Against Inhalation Anthrax in Rhesus Macaques," *Vaccine*, 16(11-12):1141-1148, 1998.
6. Anthrax Vaccine Adsorbed (BIOTHRAX) Package Insert (January 31, 2002).
7. Wright, G. G., Green, T. W, and Kanode, Jr., R. G., "Studies on Immunity in Anthrax: V. Immunizing Activity of Alum-Precipitated Protective Antigen," *Journal of Immunology*, 73:387-391, 1954.
8. 61 FR 40153, August 1, 1996.
9. "Table of Reportable Events Following Vaccination," *http://www.vaers.org/reportable.htm.*
10. "Guidance for Industry: How to Complete the Vaccine Adverse Event Reporting System Form (VAERS-1)," September 1998, *http://www.fda.gov/cber/gdlns/vaers-1.pdf.*
11. "Estimated Vaccination Coverage with 3+DTP Among Children 19-35 Months of Age by Race/Ethnicity, and by State and Immunization Action Plan Area - U.S., National Immunization Survey, Q3/2000 - Q2/2001," *http://www.cdc.gov/nip/coverage/NIS/00-01/tab19-3dpt_race_iap.htm.*
12. "Protecting our Kids: What is causing the current shortage in childhood vaccines? - Testimony Before the Committee on Governmental Affairs, United States Senate," June 12, 2002," *http://www.cdc.gov/nip/news/testimonies/vac-shortages-walt-6-12-2002.htm.*
13. Colditz, et al., "Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta Analysis of the Published Literature," *Journal of the American Medical Association*, 271:698-702, 1994.
14. Centers for Disease Control and Prevention, "Prevention of Plague: Recommendations of the Advisory Committee on Immunization Practices (ACIP)," Morbidity and Mortality Weekly Report, 45 (No. RR-14), 1996.
15. *http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3755t1.pdf*
16. *http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3805t2_01.pdf*
17. *http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3805t2_02.pdf*
18. *http://www.fda.gov/ohrms//dockets/ac/02/transcripts/3842t1.pdf*
19. *http://www.fda.gov/cber/gdlns/leverhnbk.pdf*

80N-0208

BKG-3